vs
EXACT SCIENCES CORP（EXAS）与PLEXUS CORP（PLXS）财务数据对比。点击上方公司名可切换其他公司
PLEXUS CORP的季度营收约是EXACT SCIENCES CORP的1.2倍（$1.1B vs $878.4M），PLEXUS CORP净利率更高（3.8% vs -9.8%，领先13.6%），EXACT SCIENCES CORP同比增速更快（23.1% vs 9.6%），过去两年EXACT SCIENCES CORP的营收复合增速更高（17.4% vs 7.9%）
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
Plexus Corp是总部位于美国密歇根州特洛伊市的软件企业，专注于开发及推广Plex制造云产品，这是一款面向制造行业的SaaS模式云计算ERP解决方案，可助力制造企业实现数字化运营管理升级。
EXAS vs PLXS — 直观对比
营收规模更大
PLXS
是对方的1.2倍
$878.4M
营收增速更快
EXAS
高出13.5%
9.6%
净利率更高
PLXS
高出13.6%
-9.8%
两年增速更快
EXAS
近两年复合增速
7.9%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $878.4M | $1.1B |
| 净利润 | $-86.0M | $41.2M |
| 毛利率 | 70.1% | 9.9% |
| 营业利润率 | -9.4% | 5.1% |
| 净利率 | -9.8% | 3.8% |
| 营收同比 | 23.1% | 9.6% |
| 净利润同比 | 90.1% | -19.9% |
| 每股收益（稀释后） | $-0.45 | $1.51 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EXASPLXS
| Q1 26 | — | $1.1B | ||
| Q4 25 | $878.4M | — | ||
| Q3 25 | $850.7M | — | ||
| Q2 25 | $811.1M | — | ||
| Q1 25 | $706.8M | — | ||
| Q4 24 | $713.4M | — | ||
| Q3 24 | $708.7M | — | ||
| Q2 24 | $699.3M | — |
净利润EXASPLXS
| Q1 26 | — | $41.2M | ||
| Q4 25 | $-86.0M | — | ||
| Q3 25 | $-19.6M | — | ||
| Q2 25 | $-1.2M | — | ||
| Q1 25 | $-101.2M | — | ||
| Q4 24 | $-864.6M | — | ||
| Q3 24 | $-38.2M | — | ||
| Q2 24 | $-15.8M | — |
毛利率EXASPLXS
| Q1 26 | — | 9.9% | ||
| Q4 25 | 70.1% | — | ||
| Q3 25 | 68.6% | — | ||
| Q2 25 | 69.3% | — | ||
| Q1 25 | 70.8% | — | ||
| Q4 24 | 69.0% | — | ||
| Q3 24 | 69.4% | — | ||
| Q2 24 | 69.8% | — |
营业利润率EXASPLXS
| Q1 26 | — | 5.1% | ||
| Q4 25 | -9.4% | — | ||
| Q3 25 | -3.0% | — | ||
| Q2 25 | -0.3% | — | ||
| Q1 25 | -13.6% | — | ||
| Q4 24 | -122.8% | — | ||
| Q3 24 | -5.6% | — | ||
| Q2 24 | -3.8% | — |
净利率EXASPLXS
| Q1 26 | — | 3.8% | ||
| Q4 25 | -9.8% | — | ||
| Q3 25 | -2.3% | — | ||
| Q2 25 | -0.1% | — | ||
| Q1 25 | -14.3% | — | ||
| Q4 24 | -121.2% | — | ||
| Q3 24 | -5.4% | — | ||
| Q2 24 | -2.3% | — |
每股收益（稀释后）EXASPLXS
| Q1 26 | — | $1.51 | ||
| Q4 25 | $-0.45 | — | ||
| Q3 25 | $-0.10 | — | ||
| Q2 25 | $-0.01 | — | ||
| Q1 25 | $-0.54 | — | ||
| Q4 24 | $-4.69 | — | ||
| Q3 24 | $-0.21 | — | ||
| Q2 24 | $-0.09 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $964.7M | $248.8M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.4B | $1.5B |
| 总资产 | $5.9B | $3.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EXASPLXS
| Q1 26 | — | $248.8M | ||
| Q4 25 | $964.7M | — | ||
| Q3 25 | $1.0B | — | ||
| Q2 25 | $858.4M | — | ||
| Q1 25 | $786.2M | — | ||
| Q4 24 | $1.0B | — | ||
| Q3 24 | $1.0B | — | ||
| Q2 24 | $946.8M | — |
股东权益EXASPLXS
| Q1 26 | — | $1.5B | ||
| Q4 25 | $2.4B | — | ||
| Q3 25 | $2.5B | — | ||
| Q2 25 | $2.5B | — | ||
| Q1 25 | $2.4B | — | ||
| Q4 24 | $2.4B | — | ||
| Q3 24 | $3.2B | — | ||
| Q2 24 | $3.2B | — |
总资产EXASPLXS
| Q1 26 | — | $3.2B | ||
| Q4 25 | $5.9B | — | ||
| Q3 25 | $5.9B | — | ||
| Q2 25 | $5.8B | — | ||
| Q1 25 | $5.7B | — | ||
| Q4 24 | $5.9B | — | ||
| Q3 24 | $6.7B | — | ||
| Q2 24 | $6.7B | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $151.7M | — |
| 自由现金流经营现金流 - 资本支出 | $120.4M | — |
| 自由现金流率自由现金流/营收 | 13.7% | — |
| 资本支出强度资本支出/营收 | 3.6% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $356.8M | — |
8季度趋势，按日历期对齐
经营现金流EXASPLXS
| Q1 26 | — | — | ||
| Q4 25 | $151.7M | — | ||
| Q3 25 | $219.9M | — | ||
| Q2 25 | $89.0M | — | ||
| Q1 25 | $30.8M | — | ||
| Q4 24 | $47.1M | — | ||
| Q3 24 | $138.7M | — | ||
| Q2 24 | $107.1M | — |
自由现金流EXASPLXS
| Q1 26 | — | — | ||
| Q4 25 | $120.4M | — | ||
| Q3 25 | $190.0M | — | ||
| Q2 25 | $46.7M | — | ||
| Q1 25 | $-365.0K | — | ||
| Q4 24 | $10.7M | — | ||
| Q3 24 | $112.6M | — | ||
| Q2 24 | $71.2M | — |
自由现金流率EXASPLXS
| Q1 26 | — | — | ||
| Q4 25 | 13.7% | — | ||
| Q3 25 | 22.3% | — | ||
| Q2 25 | 5.8% | — | ||
| Q1 25 | -0.1% | — | ||
| Q4 24 | 1.5% | — | ||
| Q3 24 | 15.9% | — | ||
| Q2 24 | 10.2% | — |
资本支出强度EXASPLXS
| Q1 26 | — | — | ||
| Q4 25 | 3.6% | — | ||
| Q3 25 | 3.5% | — | ||
| Q2 25 | 5.2% | — | ||
| Q1 25 | 4.4% | — | ||
| Q4 24 | 5.1% | — | ||
| Q3 24 | 3.7% | — | ||
| Q2 24 | 5.1% | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EXAS
| Screening | $695.1M | 79% |
| Precision Oncology | $183.2M | 21% |
PLXS
| Asia-Pacific | $612.0M | 57% |
| Americas | $345.0M | 32% |
| Europe, Middle East and Africa | $118.0M | 11% |
